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TargetingTherapeutic gene silencing promises signiﬁcant progress in pharmacotherapy, including considerable expansion
of the druggable target space and the possibility for treating orphan diseases. Technological hurdles have compli-
cated the efﬁcient use of therapeutic oligonucleotides, and siRNA agents suffer particularly from insufﬁcient
pharmacokinetic properties and poor cellular uptake. Intense development and evolution of delivery systems
have resulted in efﬁcient uptake predominantly in liver tissue, in which practically all nanoparticulate and lipo-
somal delivery systems show the highest accumulation. The most efﬁcacious strategies include liposomes and
bioconjugations with N-acetylgalactosamine. Both are in early clinical evaluation stages for treatment of liver-
associated diseases.
Approaches for achieving knockdown in other tissues and tumors have been proven to be more complicated.
Selective targeting to tumors may be enabled through careful modulation of physical properties, such as particle
size, or by taking advantage of speciﬁc targeting ligands. Signiﬁcant barriers stand between sufﬁcient accumula-
tion in other organs, including endothelial barriers, cellular membranes, and the endosome. The brain, which is
shielded by the blood–brain barrier, is of particular interest to facilitate efﬁcient oligonucleotide therapy of
neurological diseases. Transcytosis of the blood–brain barrier through receptor-speciﬁc docking is investigated
to increase accumulation in the central nervous system.
In this review, the current clinical status of siRNA therapeutics is summarized, as well as innovative and promising
preclinical concepts employing tissue- and tumor-targeted ligands. The requirements and the respective
advantages and drawbacks of bioconjugates and ligand-decorated lipid or polymeric particles are discussed.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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. This is an open access article under1. Introduction— oligonucleotide therapeutics
The concept of RNA interference remains to be hugely promising for
therapeutic purposes [1–5]. Taking advantage of the available human
genomic data, therapeutic oligonucleotide agents can be designedthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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every single gene can be down regulated by the powerful RNAi
mechanism, and even separate transcripts, mutations or splice variants
can often be speciﬁcally targeted. This new possibility offers quick and
easy drug development based on gene functionality, contrasting the
complicated search for active agents by traditional means.
Depending on their mechanism of action, therapeutic oligonucleo-
tides are categorized into several classes: Antisense [6,7], aptamers [8],
splice correcting oligonucleotide [9,10], siRNA [1], miRNA mimics and
antagonists [11], immunomodulating agents [12] and decoys [13] are
themost important ones. Because of the incredibly efﬁcient intracellular
RNAi machinery, siRNA and miRNA oligonucleotides currently hold the
highest promise for therapeutic purposes. Despite their partially
contrasting biological effects, the most important features in terms of
drug development are shared by all of these compound classes.
Oligonucleotides are rather large molecules (at least compared to “clas-
sical” small molecule drugs), howevermuch smaller thanmost proteins
such as monoclonal antibodies. Together with their polyanionic and
hydrophilic character, the in vivo distribution and cellular uptake are
critically and predominantly negatively determined by these traits. In
particular, chemical structures and pharmaceutical formulations
essentially inﬂuence the pharmacodynamic and pharmacokinetic
characteristics [7].
By acting on transcriptional pathways, gene silencing oligonucleotide
agents offer newmodalities for currently untreatable diseases, including,
but not being limited to cancer, viral infections, autoimmune diseases,
and cardiovascular disorders. Although these promising properties have
been known for decades, there are currently only two oligonucleotide
drugs on the market, with one more approved, but no longer marketed.
The ﬁrst drug of this class to reach marketing approval was fomivirsen,
an antisense oligonucleotide for the treatment of cytomegalovirus
(CMV) infections through local application by intraocular injections
[14]. Because of the low demand caused by the introduction of effective
HIV therapies, fomivirsen is no longer available. Pegaptanib is an aptamer
available for local therapy of age-related macular degeneration, and
antagonizes the detrimental effects of the vascular endothelial growth
factor (VEGF) [15]. The antisense oligonucleotide mipomersen has been
approved by the FDA in 2013 for therapy of familial hypercholesterol-
emia. Mipomersen inhibits the transcription of apolipoprotein B 100
and reduces blood levels of cholesterol, LDL-C, and apolipoprotein B
[16]. It represents the ﬁrst systemically applied oligonucleotide.
Mipomersen acts mainly in hepatocytes, and because of its chemical
modiﬁcations, it shows signiﬁcant accumulation in the liver. Renal
elimination is prevented by extensive binding to plasma proteins. The
tendency of mipomersen to induce an elevation of the plasma levels of
liver alanine transaminase (ALT) and aspartate transaminase (AST), and
hepatosteatosis have triggered controversy during the approval process-
es on both sides of the atlantic [5]. As the end result, mipomersen was
approved in the USA for treatment of severe homozygous familiar
cholesterolemia, but only with speciﬁc restrictions. In Europe, where
the marketing request also encompassed less severe heterozygous
forms of familial cholesterolemia, mipomersen failed to achieve approval
by the EMEA because of the concerns of toxicity over long application
periods [5].
Mipomersen as a second generation antisense agent is comprised of
phosphorothioate and 2′-methoxyethyl modiﬁcations. The phosphoro-
thioate backbone is by far the most abundant chemical modiﬁcation of
the antisense class in which one non-bridging oxygen of the phosphate
is substituted by a sulfur atom [17]. This little change of the chemical
structure inﬂuences many pharmacological properties, and accounts
for increased stability against enzymatic degradation, and a high
proportion of plasma protein binding. On the ﬂip side, the high
non-speciﬁc protein afﬁnity results in signiﬁcant off-target effects,
meaning biological outcomes that are caused by interactions other
than that on the targeted gene [18,19]. Biological investigations and
the clinical evaluation of mipomersen and other antisense agents haverecently proven that these off-target effects are indeed translated to con-
siderable relevant side effects [20,21]. In particular, phosphorothioates
result in toxic events at sites of high drug concentrations, such as local
reactions at the injection site, and most importantly, hepatotoxicity
[22]. Although it is nowwell known that most of the controversial issues
of the antisense class are caused by the phosphorothioate modiﬁcation,
fully appropriate alternatives are lacking. Modiﬁcations on the ribose
(2′-methyl, methoxyethyl and other alkyl chains, as well as locked
nucleic acids (LNA)) [23,24] aptly increase enzymatic stability, but are
only efﬁcacious in combination with at least a partial phosphorothioate
backbone, which is necessary for protein binding and thus a certain
amount of unassisted cellular uptake [24,25]. Consequently, it can be
expected that next generations of antisense compounds, currently in
clinical evaluation, will show similar toxicity, but to a lower extent
because of a decrease in dosage afforded by the higher stability.
Splice-switching oligonucleotides have demonstrated encouraging
effects in rare diseases which are characterized by a loss-of-function
because of mutations or erroneous gene splicing. The orphan disease
Duchenne muscular dystrophy is caused by the expression of a
non-functional dystrophin protein due to deletion of a section of its
corresponding gene [26]. As a result, a frame-shift occurs and a
non-functional protein is expressed. By blocking a splice junction
with an oligonucleotide, the reading frame is restored, and a short-
ened, but functional protein results. Two oligonucleotides have
been developed in parallel, one phosphorothioate, drisapersen
[10], and one phosphorodiamidate morpholino oligomer (PMO),
eteplirsen [9]. While the latter has shown good clinical outcomes with
little or no adverse effects in phase II trials, initially published results
have shown a lack of signiﬁcant clinical beneﬁt for drisapersen in a
phase III trial. Follow-up analyses and further extended evaluations
are ongoing.
To date, no short interfering RNA (siRNA) has yet reached market
authorization. This is not surprising, considering the fact that RNA inter-
ference was only discovered in 1998 [27], and it took nearly a decade to
fully elucidate its mechanism and determine guidelines for sequence
design, length, chemical modiﬁcations, and formulations [28]. Thus,
clinical evaluation of potential drugs has only begun in recent years,
with several more promising approaches set to enter clinical trials
during the next few years.
2. siRNA therapeutics— efﬁcient reduction of liver targets
Just as prior efforts with therapeutic antisense and aptamer oligonu-
cleotides, initial siRNA developments focused on local administration to
the eye. An anti-VEGF siRNA, bevasiranib, was evaluated in a phase III
trial after application of the unformulated drug [29]. However, poor
clinical responses soon led to termination of this trial, emphasizing the
need for thorough and careful preclinical development instead of
rushing a poorly designed agent to clinical trials. The main issues yet
to be resolved are substrate stability, cellular uptake and endosomal
escape, and pharmacokinetics [30,31]. Being an exogenous nucleic
acid, unmodiﬁed siRNA is prone to nearly instant enzymatic degrada-
tion in body ﬂuids. Variations of the chemical structure at the ribose
or the phosphate backbone can signiﬁcantly increase the stability, and
proper modiﬁcation patterns result in negligible cleavage by nucleases.
Although many modiﬁcations are useful for increasing stability, only
few of those are also apt for keeping intact the pharmocodynamic effect
modulated by the RNAi machinery. For therapeutic applications, the
most useful siRNAmodiﬁcations are a limited number of terminal phos-
phorothioate linkages, and several 2′-O-methyl and/or 2′-F-nucleotides
scattered throughout the sequence [32,33]. These structural optimiza-
tions allow the use of unpackaged siRNA by increasing enzymatic
stability and preventing nuclease cleavage. Rapid renal ﬁltration and
elimination are not avoided [33–36]. Ample experience with antisense
compounds has proven that modiﬁcation with a phosphorothioate
backbone evades elimination and increases cellular uptake [17]. In
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modiﬁcations renders siRNA oligonucleotides unable to activate the
RNAi machinery. Consequently, chemical modiﬁcations aptly stabilize
siRNA, but need an additional targeting approach, either through ligand
conjugation or by packaging in a delivery system.
For improvement of the pharmacokinetic properties and cellular
uptake, two distinct approaches seem to be most promising: the direct
attachment of receptor-targeted ligands to the oligonucleotide for
increasing tissue-speciﬁc accumulation and uptake [37], and the
packaging in lipid particles [38] (Table 1). For the latter approach, step-
wise evolution of lipid structures and particle composition has resulted
in improved in vitro and in vivo efﬁciency over the years [39]. The cur-
rently most advanced siRNA in the clinic is Alnylam's patisiran (ALN-
TTR02), an LNP-packaged siRNA targeted at the transthyretin (ttr)
gene [3]. It is developed for treatment of transthyretin mediated amy-
loidosis, an orphan disease in which mutated proteins are misfolded
and build up amyloid deposits. Depending on the mutation's locus, the
disease results in polyneuropathy and/or cardiomyopathy, the latter
form culminates in progressive heart failure. Patisiran efﬁciently
knocked down both wild-type and mutated ttr genes and thus reduces
TTR protein production in phase II trials. A sustained effect of an 80%
TTR reduction was achieved for several weeks after a single dose and
six months after multiple dosing. The multi-center phase III APOLLOTable 1
Selection of ongoing clinical trials of siRNA agents. Respective delivery systems and chemical m
(focusing on local administration of unformulated siRNA), and ongoing trials (systemic applica
Compound Application route Formulation/modiﬁcation Target
Bevasiranib Intravitreal – VEGF
AGN-745 (Sirna027) Intravitreal – VEGF
ALN-RSV01 Inhalation – RSV
nucleocapsid
gene
RXI109 Intradermal Asymmetric siRNA with
phosphorothioates and
lipophilic ligands
Connective
tissue growth
factor
QPI-1002 Intravenous Modiﬁed siRNA
(alternating 2′-O-Me)
p53
CALAA-01 Intravenous RONDEL™
(cyclodextrin-based
formulation with PEG and
transferrin)
M2 subunit of
ribonucleotid
reductase
Patisiran
(ALN-TTR02)
Intravenous SNALP (stable nucleic acid
lipid particles)
Transthyretin
(TTR)
ALN-TTRsc Subcutaneous GalNAc conjugate Transthyretin
(TTR)
ARC-520 Intravenous Dynamic polyconjugate
(co-injection with siRNA)
Coagulation
factor 7 (F7)
siRNA-EphA2-DOPC Intravenous Liposome (DOPC) EPHA2
TD101 Intradermal
injection/microneedle
modiﬁed siRNA (‘Accell’:
2′-O-Me, cholesterol,
phosphorothioates)
Keratin 6a
(K6a)
Atu027 Intravenous AtuPLEX® (liposome)
with AtuRNAi® (2′-O-Me)
Protein kinase
N3 (PKN3)
Atu111 Intravenous DACC lipoplex Angiopoietin-
(Ang-2)
PF-655 Intravitreal AtuRNAi® (2′-O-Me) RTP801
QPI-1007 Intravitreal Modiﬁed siRNA
(alternating 2′-O-Me)
Caspase 2
siG12D LODER Intratumoral LODER™ (PLGA matrix) mutant K-Ras
G12D
TKM-PLK1 Hepatic
intraarterial/intravenous
SNALP PLK1
ND-L02-s0201 Intravenous Vitamin A coupled lipid
nanoparticles
HSP47
DCR-MYC Intravenous Lipid nanoparticles
(EnCore)
MYCtrial for evaluation of clinical effects on neurological symptoms, motor
and sensory nerve functions and heart function has begun in late 2013.
The same company is developing an anti-TTR-siRNA sequence as a
bioconjugate for subcutaneous application for treating TTR-amyloid-
induced cardiomyopathies. As a targeting ligand, N-acetylgalactosamine
(GalNAc) is attached to the sense strand of siRNA using a trivalent linker
to achieve receptor-mediated endocytosis via the asialoglycoprotein
receptor [40–42]. In a phase I test in humans, TTR was reduced in a
dose-dependent manner with a maximum of up to 94% reduction after
application of 10 mg/kg siRNA conjugate. The trivalent GalNAc linkage,
i.e. attachment of three molecules of the targeting carbohydrate to one
siRNA molecule, ensures high afﬁnity to the receptor, decreases the Kd
and thus enhances cellular uptake in mouse hepatocytes around ten-
fold compared to a divalent conjugate [42]. Biodistribution data in vivo
suggest that a high proportion (N50%) of the applied dose is delivered
to the liver. When using bioconjugation to afford siRNA targeting and
uptake, the metabolic stability needs to be increased because of the lack
of shielding in extracellular tissues and blood circulation. Thus, chemical
modiﬁcation of the siRNA is more important than for LNP-mediated
delivery. A well-attuned combination of nucleotide modiﬁcations (2′-O-
Me, 2′-F, 2′-desoxy) together with several terminal phosphorothioate
linkages not only increases the half-life of the agents, but also enhances
the target knockdown efﬁciency in mice [42]. This was attributed to theodiﬁcations as well as administration routes are listed for illustration of early development
tions, primarily for liver-associated diseases).
Indication Company Clinical
status
Reference
Age-related macular
degeneration
Opko Health Inc. Phase III,
terminated
[29]
Age-related macular
degeneration
Allergan/Sirna Phase II,
terminated
[55]
RSV infection after lung
transplantation
Alnylam Pharmaceuticals Phase II,
completed
[56]
dermal scarring after
surgery
RXi Pharmaceuticals Phase II [57]
Delayed graft function and
acute kidney injury
Quark
Pharmaceuticals/Novartis
Phase II [58]
e
Solid tumors Arrowhead Research
Corporation
Phase I,
completed
[59]
TTR mediated amyloidosis
(FAP)
Alnylam Pharmaceuticals Phase III [3]
TTR mediated amyloidosis
(FAC)
Alnylam Pharmaceuticals Phase II [42]
Hepatitis B Arrowhead Research
Corporation
Phase II [44]
Advanced cancers MD Anderson Cancer
Center
Phase I [60]
Pachyonychia congenita TransDerm Phase I,
completed
[61]
Advanced solid cancer Silence Therapeutics Phase II [62]
2 Lung indications Silence Therapeutics Phase I [63]
Diabetic macular edema
(DME)/AMD
Quark
Pharmaceuticals/Pﬁzer
Phase II [64]
Optic nerve atrophy and
non-arteritic ischemic optic
neuropathy (NAION)
Quark Pharmaceuticals Phase I/IIa [65]
Pancreatic ductal
adenocarcinoma
Silenseed Phase I/II [66]
Liver cancer Tekmira Pharmaceuticals Phase I/II [67]
Fibrosis Nitto Denko Corporation Phase I [68]
Hepatocellular carcinoma Dicerna Pharmaceuticals Phase I [69]
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interference. The encouraging data prompted Alnylam to develop several
other siRNA agents as GalNAc conjugates including ALN-AT3 for hemo-
philia and rare bleeding disorders, ALN-HBV for hepatitis B virus
infections, and ALN-PCSsc for hypercholesterolemia.
The carbohydrate GalNAc is also utilized as a targeting agent by
Arrowhead Research Corporation for achieving targeting to and uptake
into hepatocytes of their anti-HBV siRNA [4]. Instead of covalently
attaching GalNAc to the siRNA agent, the ligand is tethered to a carrier
molecule, a mellitin-like polymer that is degraded in the acidic environ-
ment of endosomes. This so called dynamic polyconjugate carries
additional PEG-masking ligands that are likewise cleaved at acidic
pH-values, and release the previously masked cationic charge of the
polymer. This sophisticated design is supposed to increase endosomal
escape of the siRNA through the proton sponge effect, i.e. induction
of inﬂux of hydrogen ions followed by water and swelling of the
endosomes,ﬁnally causing their disruption [43].While initially presented
data on polyconjugates relied on a covalent, but labile attachment of the
siRNA cargo to the polymer via a disulﬁde linkage, a more recent evolu-
tion of the systems uses simple co-application of siRNA and the carrier
[44]. Because little interaction of the uncharged carrier with siRNA can
be expected, it is not fully clear towhat extent the polymer inﬂuences di-
rect siRNA uptake or if it is simply an adjuvant for increasing endosomal
escape. In a transgenicmousemodel, efﬁcient reduction to less than 1% of
serum viral markers was detected [4]. Evaluation in humans in a phase II
trial has lately been initiated. Early data that have been disseminated
indicated reduction of viral markers to around 50% of the baseline after
administration of siRNA at a 2 mg/kg dose. The results of higher doses
are not yet published.
The recently expanding knowledge about microRNAs (miRNA) has
quickly prompted the development of miRNA-mimicking oligonucleo-
tides for therapeutic applications [45]. A respective antagonizing
phosphorothioate/LNA-modiﬁed single stranded oligonucleotide,
miravirsen, blocks the interaction of human miR-122 with HCV RNA,
an essential step in viral replication [46]. An additional binding to
precursor pre- and pri-miR-122 structures and consequent inhibition
of nuclease-mediated miRNA processing seem to contribute to the
pharmacological effect [47]. Miravirsen is currently undergoing phase
II evaluation against HCV infections.
It is no surprise that all these clinically evaluated siRNA and miRNA
drugs, as well asmany antisense agents, are tested for the antagonization
of liver targets [48]. The most viable approaches for tissue enrichment
and cellular uptake make use of passive (lipid particles) or active
(asialoglycoprotein receptor ligand) hepatocyte targeting. Lipid particles
are directed to the liver mainly because of their size, and GalNAc
conjugates target the respective receptor mainly expressed on hepato-
cytes. These drugs will be instrumental to prove the principal efﬁcacy of
the siRNA technology and gather information about required dosing,
target validation, achieved level of gene expression reduction and corre-
sponding clinical effects. Furthermore, comprehensive drug safety assess-
ments will have implications for the whole class of siRNA therapeutics
[49,50]. For making full therapeutic use of the potency of the technology,
it is essential to develop modalities for expansion of the target space to
other organs, tissues, and tumors.
Because of their mode of action, siRNA oligonucleotide agents
instantly broaden the druggable target space to all gene transcripts.
Nearly all traditional, small molecule drugs rely on distinct binding
pockets of proteins. Consequently, the number of potentially druggable
targets is limited. The number of disease-relevant targets for small
molecules is estimated at around 1000, with less than 30% of that
number currently being exploited for therapy [51]. The advent of
therapeutic antibodies has extended the druggable target space, but
only to extracellular molecules. Because of interfering with translation,
siRNAs can target any desired gene product. Because of the challenges
associated with the pharmacokinetics and generally higher costs for
development and manufacturing compared to small molecules, themain potential virtue is the antagonization of targets that are not
available for small molecules. However, siRNAs currently only work in
one direction, that is inhibition of gene translation. As a consequence,
development programs preferably focus on diseases unavailable for
other treatment options, and on targets with validated overexpression
and disease-relevance.
Despite their intrinsic speciﬁcity on the molecular level, gene-
silencing oligonucleotides are by no means magic bullet in the sense
that side effects are excluded a priori. Both sequence-speciﬁc and
sequence-unspeciﬁc off-target effects are well-documented [19,52–54].
While the ﬁrst, caused by hybridization to nucleic acid targets other
than the intended, can be avoided by careful oligonucleotide design, the
latter is induced by binding to proteins, particularly immune-activating
receptors such as toll-like receptors [53]. Side effects can also arise from
excessive silencing of the target, especially in non-disease relevant organs
and tissues. For example, when attacking a cancer target, it is assumed
that the exaggerated expression in tumors is responsible for a higher
impact of therapeutic silencing than that in healthy cells. However,
since a certain basal expression exists in somatic tissue, the interference
with gene expression in unaffected tissue is a cause for concern. Conse-
quently, targeted delivery of siRNA is an important aspect for adding a
second layer of speciﬁcity, and like for any other therapeutic agent, prom-
ises better efﬁcacywith lower adverse effects. Of course,many issues and
formulations of targeted siRNA delivery are sharedwith delivery of other
drugs, but there are some speciﬁc aspects for oligonucleotide transport:
The polyanionic nucleic acid cargo needs to be efﬁciently packaged and
shielded from degradation. After successful cellular uptake, the oligonu-
cleotides must be released into the cytosol in order to exert their thera-
peutic effect. This is in contrast to most low-molecular weight
compounds, for which successful cytosolic transport is often not decisive.
2.1. Barriers and biodistribution
In order to reach their site of action, the cytosol, siRNA therapeutics
need to overcome a number of barriers that stand in their way [70].
After systemic (intravenous) application, siRNA agents enter the blood
circulation and undergo organ distribution, thereby avoiding degrada-
tion by nucleases and elimination through the kidney. In organs, the
compounds need to extravasate from the blood vessels to the intersti-
tium, overcoming the endothelial barrier [71]. Traveling through the
interstitial space, siRNAs are associating to target cells and are taken
up generally by endocytotic mechanisms. The endocytic vessels fuse
with endosomes, and for successfully attaining the siRNA machinery,
the oligonucleotides still have to pass through this last barrier [72,73].
All of these steps are signiﬁcantly inﬂuenced by the selected delivery
vehicle, which has to confer adequate solutions to these diverging
challenges.
Besides intravenous injections, application routes to the blood
stream include subcutaneous injection, delivery through the skin, lung
[74], or nasal mucosa [75]. Each of those ones add an additional absorp-
tion barrier to overcome, so it is no surprise that current clinical
attempts focus on intravenous and subcutaneous (for which complete
absorption can be expected) injections. First, efﬁcient delivery systems
for these routes need to be developed, which can eventually been
expanded to other application routes afterwards.
Its large accessible area and easy administration modes make the
skin an attractive target for siRNA application. The outer skin barrier is
mainly comprised of the continuous stratum corneum, an impermeable
layer of keratinocytes. The most promising possibility for large hydro-
philic agents to overcome this barrier is physical disruption by the use
of microneedles. Therapeutic siRNAs can be coated onto those stainless
steel needles, or injected with microneedle devices [76,77]. Reports
show a good epidermal uptake and gene silencing effect, but little to
no absorption into dermal capillaries and systemic circulation. Because
the use of needles on diseased skin is associated with pain, their clinical
use so far has been limited.
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action to local effects. Despite a large number of studies reporting the
successful use of siRNA in preclinical models, no clinical translation
has yet emerged [78]. For intranasal, intratracheal or inhalation delivery
systems, lipids (neutral and cationic), polymers (polyethyleneimine (PEI),
poly(lactic-co-glycolic acid) (PLGA) etc.), and inorganic carriers (calcium
phosphate, mesoporous silica particles) have been employed [74].
In the blood and other biological ﬂuids, wild-type nucleic acids are
quickly degraded, mainly by exonucleases, which cleave the phosphate
linkages between terminal nucleotides. Endonucleases, cleaving nucleic
acids at internal backbone linkages, are less frequent. Consequently,
exogenous oligonucleotides are degraded in a stepwisemanner starting
at terminal sites, yielding shortened oligonucleotides as main metabo-
lites. Both the parent compound and the metabolites are eliminated
by renal ﬁltration. The ﬁltration limit for macromolecules lies around
2–4 nm [79], translating to ca. 20–40 kDa for nucleic acids [7]. Standard
single and double stranded oligonucleotides (and their metabolites) fail
to reach this limit, but increasing the molecular size by either attach-
ment of ligands such as polyethylene glycol (PEG), incorporation into
larger particles or signiﬁcant binding to plasma proteins efﬁciently
saves siRNA from elimination [7].
On the other end of the size scale, large particles are intercepted by
the reticuloendothelial system (RES). Generally, particles above around
200 nm are rapidly cleared by phagocytic cells mainly found in the
liver and spleen [80]. However, the RES can be avoided by surface
functionalization, such as with amphiphilic PEG chains.
The endothelial barrier determines distribution into organs [81].
Macromolecules and nanoparticles extravasate primarily by convection,
with its relative contribution increasing with transcapillary volume
ﬂow. The extent of crossing the endothelial barrier is dependent on
the capillary pore size, which generally forms the upper particle size
limit [82]. Depending on the organ or tissue, the endothelial gap junc-
tions are differing from very tight (blood brain–barrier) to continuously
small (standard arteries and capillaries) and fenestrated (digestive mu-
cosa). The liver, as well as lymphoid tissue and hematopoietic organs,
comprises sinusoidal (discontinuous) capillaries. Unlike fenestrations,
these capillaries lack a diaphragm over the pore and thus show even
superior permeability, allowing exchange of macromolecules. As men-
tioned before, siRNA delivery systems have an inherent preference to
the liver. This pertains to lipid-based particles, cationic and neutral
nanoparticles, and lipophilic ligands in bioconjugates. Liver accumula-
tion is caused by the discontinuous nature of the hepatic vasculature
(for nanoparticles and protein bound oligonucleotides) or the lipid
metabolism (liposomes and lipid or cholesterol conjugates). Within
the liver, the use of a speciﬁc receptor-targeted ligand can be useful to
distinguish between the different hepatic cells and prevent an accumu-
lation in Kupffer cells, the resident macrophages in this organ. Thus,
trivalent GalNAc conjugates increase uptake into hepatocytes and
consequently gene silencing in this cell type [42]. The asialoglycoprotein
receptor is characterized by efﬁcient endocytosis.
Several diseases show altered capillary permeability in affected
organs, and particularly tumors are characterized by increased pore
size, thus allowing the passage of larger molecules and particles. This
peculiarity is known as enhanced permeability and retention (EPR)
effect [83]. Because of the leaky vasculature together with the lack of
lymphatic drainage, the EPR effect offers an attractive option for passive
targeting of nanoparticles to tumors. Indeed, the EPR effect has been
exploited comprehensively by researchers and has been used to explain
nanoparticle tumor accumulation in mouse models [84]. On the other
hand, passive nanoparticle targeting only amounts to up to 20% accu-
mulation in tumors (often it is much less), and the extent of vasculature
leakage is varying depending on tumor type and other factors [85].
Perivascular tumor growth, intratumoral pressure, and angiogenesis
rate all contribute to the heterogenicity of the EPR effect, which varies
substantially between tumor model, individual patients and even
within a single tumor [86]. Because tumors in animal xenograft modelsgrow much faster than those in humans, the vasculature pores are
generally larger in the preclinical models, which often results in an
overinterpretation of the EPR effect. A clear clinical proof of its relevance
for nanoparticle tumor targeting in a therapeutic setting remains to be
shown [83].
The blood–brain barrier (BBB) is characterized by its unique
tightness, preventing free diffusion into the brain. For therapeutic
purposes, only highly lipophilic molecules with a molecular weight
under 400 Da or those with an active transport system can access the
brain [87]. Biomacromolecules and untargeted nanoparticle delivery
systems suffer from negligible diffusion or transcytosis through the
blood–brain barrier. Speciﬁc active transport mechanisms for nucleic
acids are lacking, and thus other strategies for BBB transcytosis need
to be developed. While the BBB exhibits some speciﬁc extracellular
markers, most if not all endothelial receptors are also found in certain
abundance in other endothelial tissues.
To avoid hepatic accumulation and achieve signiﬁcant siRNA gene
silencing in other organs, the use of receptor-speciﬁc targeting ligands
seem to be mandatory.
2.2. Cellular uptake and intracellular trafﬁcking
After extravasation and crossing the interstitium, the cell membrane
barrier poses the next hurdle. A lot of data has been generated and
discussed regarding this last and maybe most difﬁcult hurdle [88,89].
It seems clear that the endocytosis pathway is dominating siRNA
uptake, whether in naked or conjugated form, or in a delivery system.
There are several pathways of endocytosis, the clathrin-coated pit
pathway, the caveolar-dependent uptake, clathrin- and caveolin-
independent pathways, and macropinocytosis [90–93]. Phagocytosis is
restricted to specialized cells, such as macrophages, granulocytes and
Kupffer cells. All these uptake mechanisms have been reviewed in
depth elsewhere [89,94]. Although there are small, but important
differences between these mechanisms, in nearly all cases of functional
uptake, the siRNA agent ends up in an endosomal vesicle [89].
The crucial point of achieving functionally active siRNA uptake is
considered to be endosomal escape rather than endocytosis. Generally,
only few molecules of siRNA seem to be transported into the cytosol
from early or late endosomes and thus avoid being degraded in
lysosomes. There is a reasonably detailed, yet not fully complete under-
standing of the intracellular endosome trafﬁcking [91]. The endosomal
system is characterized by a great extent of recycling, i.e. the return of
the vesicles to the cell surface. Cargoes taken up through the distinct
pathways all end up in early endosomes. Early endosomes act as a cen-
tral sorting place, and deﬁne the subsequent fate of the internalized
components, either towards recycling back to the surface ormaturation
into late endosomes and lysosomes and eventually deciding delivery to
a target compartment. Association of cytosolic proteins to their side of
endosomal membranes is instrumental in their further fate. The Rab
family, especially Rab5, is a key regulatory component for this process
and, together with other coating proteins, decisive for selection of the
targeted cell compartment [95]. Motor proteins are responsible for
directed movement along actin- and tubulin ﬁlaments to reach the
target organelles [96]. Despite the dissection of this fascinating and
well-orchestrated intracellular machinery, the gathered knowledge
has not yet been translated into smart design of delivery systems that
can enhance endosomal escape by rational means. It is largely unclear
how and to which extent siRNA delivered in liposomes or polymers or
tethered to receptor-speciﬁc ligands is eventually reaching the cytosol.
Rational attempts to increase endosomal escape have not really relied
on the molecular basis of these processes; instead they have tried to
make use of physical mechanisms. The so called proton sponge effect
is characterized by an inﬂux of hydrogen ions into lysosomes caused
by acidiﬁcation of a basic macromolecule (peptide, polymer, or small
molecule) [97,98]. The subsequent swelling and disruption of the vesi-
cles is intended to result in cytosolic release of its cargo. The induction
6 C. Lorenzer et al. / Journal of Controlled Release 203 (2015) 1–15of membrane fusion events, for example by proteins and peptides
which alter their conﬁrmation in the acidic pH of endo- and lysosomes
and then fuse with themembranes to increase permeability, is a further
strategy to increase cytosolic deliver of siRNA [99]. However, these
approaches have not really resulted in a convincing increase of siRNA
effects in a therapeutic setting, and safety precautions need to be met.
An exploitation of the increasing knowledge of the molecular
mechanisms of endosomal sorting and trafﬁcking could certainly help
improving the endosomal escape of oligonucleotides in the future.
It is obvious that an interplay of several parameters are decisive
for the biodistribution and successful intracellular delivery of siRNA
agents, whether as a molecule or in a nanoparticle. These parameters
include molecule/particle size, charge, stability, eventual surface
functionalization, and the presence of a receptor-mediated targeting
ligand.
2.3. Targets and ligands for BBB transcytosis
Based on disease areas with unmet medical need, functional siRNA
delivery into tumors [100], the brain [101], and endothelium [99] is
especially attractive. For selective targeting, surface receptors with ex-
clusive or highly predominant expression in those organs, tissues, or tu-
mors are required. Because of similarities between endothelial tissues
and the heterogeneity of tumor expression patterns, this is by no
means a trivial task (Table 2).
For siRNA delivery across the BBB, the transferrin receptor is most
frequently targeted because of its ability to trigger transcytosis [102,
103]. Other targets that have been used for BBB-targeting of siRNA in-
clude the insulin receptor [104], and the LDL receptor [105]. Transferrin
receptor targeted delivery has shown some success for protein and drug
uptake into the brain [102,106] but in other cases, trapping in the brain
microvasculature has been reported [107,108]. Recently, a more
detailed insight into the mechanisms has revealed that the afﬁnity (or
avidity) of the peptide or protein ligand to the transferrin receptor is
crucial in deciding the fate [103,106,109]. High afﬁnity proteins show
less brain accumulation than their counterparts with lower afﬁnity to
the transferrin receptor. Using in vivo imaging, it was shown that high
afﬁnity ligands induced trafﬁcking to lysosomes and degradation
[103]. Thereby the level of expressed transferrin receptor was reduced,
which even lowered the efﬁciency of a second dose. A ligandwith lower
afﬁnity was transported into the brain to a higher extent, obviously by
avoiding lysosomal degradation [109].Table 2
Targeted siRNA delivery systems for brain, leukocytes, and tumors. Receptor-speciﬁc ligands a
bioconjugates).
Tissue Ligands Target
Blood–brain-barrier Transferrin antibody
transferrin-targeted fusion peptide
Transferrin receptor
Rabies virus glycoprotein (RVG) Not identiﬁed
nAChR, NCAM, and p
Leukocytes Integrin antibody Integrins
Tumor tissues Folate Folate-receptor
Hyaluronic acid CD44
Antibody
afﬁbody
Her-2 receptor
Anisamide Sigma receptor
Designed ankyrin repeat protein Epithelial cell adhesio
EGFR-targeted peptide EGF-receptor
Bombesin-like histidine-rich peptide BB2
EGFR-, vimentin-targeted peptides EGF-receptorA number of delivery systems for nucleic acids have shown to signif-
icantly increase brain accumulation several-fold [110]. A selection of
peptide and protein targeting ligands (holo-transferrin, a transferrin an-
tibody, mutated diphtheria toxin, angiopep-2, and an apoE-mimicking
peptide) was grafted onto liposomes for blood-brain barrier targeting.
Only the liposomes with transferrin antibody resulted in signiﬁcantly
higher brain accumulation, but the amount of brain uptake was still
agonizingly low with less than 0.1% of the injected dose reaching the
central nervous system in an in vivomodel, and the largest proportion
ending up in the liver [110]. No signiﬁcant decrease of the particles
compared to the untargeted system in other organs was detected. It is
unclear whether the other four failed due to inefﬁcient binding to the
antigen, or other factors such as altered extravasation or insufﬁcient
antigen expression in vivo.
For gene delivery, liposomes decorated with monoclonal antibodies
against the transferrin and insulin receptors and PEG chains for “stealth”
delivery were employed in several reports [104]. In a xenograft glioma
mouse model, a liposome with two different monoclonal antibodies,
one against the rat transferrin receptor, and one against the human
insulin receptor, actively transported an expression plasmid for RNA
interference to the tumor [111]. Efﬁcient silencing of the targeted EGF-
receptor and increased survival time was reported. It is not clear if this
approach would be successful for oligonucleotide delivery for which a
higher intracellular target accumulation would be necessary.
In a recent report, a fusion peptide consisting of a transferrin-
targeted sequence andmyristoylated transportanwas used for conden-
sation and selective brain-uptake of siRNA [112]. Uptake and silencing
in a luminescence assay was increased compared to a peptide lacking
the transferrin sequence. Transport across a bEND3 monolayer in a
transwell assay was likewise enhanced by the transferrin-targeted
peptide. The carrier was not yet evaluated in vivo, and because a certain
degree of uptake is possibly mediated by the transportan fraction, the
speciﬁcity of the system cannot yet be reliably assessed.
The rabies virus glycoprotein (RVG) was recently used repeatedly to
afford siRNA delivery across the blood–brain barrier [113–117]. This 29
amino acid peptide is the required component for attachment and
uptake of rabies viruses to host cells [118]. The surface receptor that is
responsible for interaction with RVG and the exact mechanism of inter-
nalization remain elusive [119]. Several molecules have been identiﬁed
as potential receptors, including the nicotinic acetyl choline receptor,
the neuronal cell adhesion molecule (NCAM), and the low-afﬁnity
nerve growth factor receptor (p75NTR). None of those seems to bere paired with the respective molecular targets and siRNA-formulations (nanoparticles or
Formulation
− Liposomes [110]
− Peptide/siRNA complexes [112]
75NTR are possible targets
− Peptide/siRNA complexes [113]
− Polyethyleneimine complexes [115]
− Liposomes [116]
− PAMAM nanoparticles [117]
− Targeted exosomes [114]
− Protamine-antibody/siRNA complexes [126]
− Liposomes [127]
− Polythyleneimine complexes [135–137]
− PEG–siRNA conjugate [138]
− Self-assembled nanoparticles [145]
− Hyaluronic acid-graft-poly(dimethylaminoethyl
methacrylate) (HPD) conjugate complexes [140]
− Chitosan/quantum dot nanoparticles [132]
− Bionanocapsule/liposome complexes [141]
− Conjugate [142]
− Lipid/protamine nanoparticles [144]
n molecule − Nanocomplexes [154]
− Chitosan nanoparticles [133]
− Conjugate [146]
− Proteinticle [156]
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knockout models still show susceptibility to infections [118]. Instead,
available data indicates that more than one receptor may be used for
neuronal uptake of RVG. It is unclear how RVG mediated transport to
the brain, since the identiﬁed receptors are localized in neurons, but
not at the blood–brain barrier endothelium. Considering the transport
of rabies viruses by retrograde axonal transport, a possible explanation
could be the uptake into peripheral neurons reaching beyond the
blood–brain barrier.
For utilization of the efﬁcient CNS-targeting properties of RVG, the
peptide was fused with a nona-arginine for complexation of nucleic
acid cargo [113]. The system speciﬁcally transfected neuronal cells,
and successfully delivered the siRNA cargo to the brain, where it trig-
gered gene knockdown. Similar systems were generated by attaching
the RVG peptides to PEI [115], liposomes [116], and polyamidoamine
(PAMAM) dendrimers [117]. When attached to highly charged, spheri-
cal PAMAM dendrimers, RVG greatly increased brain accumulation
compared to untargeted PAMAM [117]. After tail vein injections,
liposomeswith RVG grafted to their surface showed high brain accumu-
lation, while liposomes without a targeting ligand or with cRGD were
not able to traverse the blood–brain barrier [116]. Likewise, a branched
PEI carrier was conjugatedwith the RVG peptide through disulﬁde link-
ages [115]. This system speciﬁcally increased uptake into Neuro2a
cell in vitro and showed signiﬁcant brain accumulation in vivo. Likely
caused by its larger size, considerable uptake into phagocytic liver cells
was also observed. Neuronal uptake was blocked by competition with
bungarotoxin, which binds to the nicotinic acetylcholine receptor [113].
Uptakewas also inhibited byGABA, suggesting a role of theGABAB recep-
tor [117].
The attractiveness of the RVG peptide is further illustrated by its use
for targeting of exosomes. These extracellular biological particles are a
class of membrane vesicles and contribute to the horizontal transfer of
small RNAs between cells [120]. Formed from endosomal compart-
ments within a cell, endocytic vesicles can be released extracellularly
to form exosomes. In contrast to other membrane vesicles, exosomes
are generally smaller, with a diameter of around 100 nm [121]. Using
an exosome systemwith surface expression of the RVG-peptide for ace-
tylcholine receptor targeting, successful siRNA-mediated gene silencing
inmouse brainwas reported [114]. Both GAPDH and BACE1 genes were
shown to be successfully knocked down after intravenous application of
RVG-exosomes. Exosomes seem to proﬁt from a lower accumulation
rate in the liver, although no comprehensive biodistribution data is
available. In the aforementioned study with RVG-exosomes and
untargeted exosomes, no down regulation of GAPDH was found in the
liver, but a biodistribution study using labeled exosomes was not per-
formed. Thus, it remains unclear whether exosomes are not accumulat-
ed in the liver because of their unique characteristics and/or smaller size
thanmost other delivery systems, or they only fail to release their cargo
in liver cells in a sufﬁcient quantity. In another study using intranasal
administration, no liver accumulation was detected for both exosomes
(30–100 nm) and microparticles (0.5–1 μm). While the smaller parti-
cles were effectively transported into the brain, the microparticles
were deposited in the lung, but failed to reach the bloodstream [122].
EGFR-targeted exosomes injected into the tail vein on the other hand
showed signiﬁcant liver accumulation [123].
2.4. Targets and ligands for leukocytes and endothelium
Integrins are the biggest family of cell adhesion molecules [124].
Being heterodimer proteins consisting of an α and a β subunit, they
mediate cell–matrix and cell–cell interactions in physiological and
pathological contexts. Their wide expression on cellular surfaces and
their constitutive efﬁcient internalization make them attractive targets
for receptor-mediated drug transport. Among the 24 integrin family
members, β2 and β7 integrins are exclusively expressed on leukocytes
[125]. The distribution of α8 in mammalian species is unique amongintegrins with high abundance in vascular and visceral smooth muscle,
kidney glomeruli and alveoli. In the alveolar walls of the rat lung, the
cells stained with anti-α8 antibody are likely alveolar myoﬁbroblasts,
contractile cells located in the alveolar interstitium. Alveolar
myoﬁbroblasts are situated along the capillaries and adjacent to
the alveolar epithelium and basement membrane. Other integrins
are commonly found on tumor vasculature, and can be targeted for
oncologic purposes.
The tissue distribution of an integrin may provide insight into its
function. Although some integrin heterodimers are widely expressed
by a variety of cell types (e.g.α2β1,α3β1), others have a restricted distri-
bution. TheαIIb subunit is expressed only in platelets and functions as a
primary mediator of platelet aggregation. Tumor endothelial cells show
an increased expression of αVβ3, and the β2 and β7 subunits are almost
exclusively found in leukocytes. The expression of most integrins is
developmentally regulated. For example, the α4β1 integrin is widely
distributed during embryonic development, but is restricted to leuko-
cytes and endothelial cells in normal adult tissues.
For leukocyte targeting, integrin antibody-based speciﬁc delivery
systems were generated. An antibody targeted to the integrin LFA-1
(containing the leukocyte-speciﬁc β2 subunit) was fused to a protamine
fragment for complexation of siRNA [126]. The systemwas successful in
delivering siRNA in vivo into exogenous K562 cells engineered to ex-
press the human LFA-1 receptor. No siRNA uptake was found in murine
cells. In a similar approach, an antibody binding to the β7 integrin
subunit was grafted onto the surface of liposomes via hyaluronan
[127] that was complexed to siRNA via protamine. Both integrin
targeted delivery systems resulted in speciﬁc gene silencing in leuko-
cytes. The biodistribution of labeled lipid particles was examined and
increased accumulation in the inﬂamed gut by about 3.5-fold was de-
tected. As with untargeted particles, signiﬁcant localization in liver
and spleen was also found, indicating a size-dependent preference to
these organs.
The increased expression ofαVβ3 integrin on tumor endothelial cells
was exploited for delivery of siRNA through a cationic lipid systemwith
cyclic RGD grafted onto its surface [128]. In vitro, the integrin presence
was essential for successful uptake and gene silencing, and in vivo, the
targeted system resulted in siRNA-mediated gene silencing in tumor en-
dothelial cells, but not in other endothelia. The biodistribution pattern
was altered by attachment of the peptide ligand, and increased accumu-
lation was found in spleen, lung and the kidneys, at the expense of liver
accumulation. However, while a relative higher percentage of the dose
ended up in other organs, more than 50% were still localized in hepatic
tissues.
RGD peptides were also attached to the surface of PAMAM
dendrimers [129,130]. Due to the strong inherent binding and transfec-
tion potency of dendrimers, which are mediated by charge interactions
with cellular membranes, uptake was not increased through ligand at-
tachment. However, deeper penetration into tumor spheroids resulted
by binding of RGD to integrin αVβ3 [130], caused by interfering with
the interaction of integrin with the extracellular matrix.
The cyclic RGD peptide has been attached to siRNA for speciﬁc
targeting of αvβ3 integrin-positive cells [131]. The cellular uptake was
increased with progressive RGD valency, but no clear correlation of up-
take with the biological effect was found. Only tri- and tetravalent con-
jugates actively reduced the targeted luciferase reporter gene, and
unlike the results for uptake, a saturation of the effect at an siRNA con-
centration of 50 nM was detected.
2.5. Targets and ligands for tumors
For targeting oligonucleotides to tumors, several other frequently
overexpressed surface receptors have been aimed at. An ideal receptor
for tumor targeting would be only expressed on malignant cells with
very limited expression on somatic cells. Moreover, the receptor needs
to be accessible, distributed evenlywithin the tumor, and bound ligands
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all criteria, and the heterogenicity of tumors with their ability for rapid
resistance development further complicates successful tumor targeting.
For siRNA delivery, frequently targeted receptors include Her2 [132],
the epidermal growth factor receptor EGFR [133], and the epithelial
cell adhesion molecule EpCAM [134].
The folate receptor is also expressed frequently on cancer cells, and
is an attractive option for speciﬁc targeting. Several reports have
employed folate receptor targeting for siRNA using different linkages
[135,136]. A nanoparticulate system consisting of dextran and LPEI
was used for folate-receptor speciﬁc delivery of siRNA [137]. Both
siRNA (via a disulﬁde bond) and folate were ﬁrst covalently attached
to dextran, before condensationwith PEI. In vivo, this system successful-
ly reduced GFP expression in a xenograft model, and compared to
siRNA/LPEI complexes, altered the biodistribution pattern towards
increased accumulation in the tumor. While the amount found in the
liver was unchanged, the increased tumor accumulation was correlated
with reduced amounts in spleen. Similar PEI based systems were
engineered for folate-mediated targeting and evaluated in vitro or in
xenograft in vivomodels [135,138,139].
Hyaluronic acid is a glycosaminoglycan that is found widely distrib-
uted throughmany tissues, including epithelium and neuronal tissue. It
is formed in plasmamembranes, is amain component of the extracellular
matrix and contributes to cell migration, proliferation and tumor growth.
Thismacromolecule is a ligand for CD44,which is overexpressed inmany
tumors [140]. Conjugation of hyaluronic acid with a polymeric cationic
carrier was used as a delivery system for siRNA for speciﬁc tumor
targeting [141]. In a xenograft mouse model, a crosslinked version of
this carrier system efﬁciently delivered siRNA to the tumor site and
resulted in gene silencing of the targeted ﬂuorescent reporter protein.
For Her2-mediated targeting, a recent report used particles consisting
of hepatitis B virus L protein, the viral surface antigen (HBsAg), a lipid bi-
layer, and a Her2-selective afﬁbody [142]. The system showed good
in vitro selectivity for Her2-positive cells followed by successful gene si-
lencing. In vivo biodistribution data has not yet been reported.
For tumor targeting, anisamide, a ligand for sigma receptors, has
been used [143]. Grafted to the surface of lipid/protamine siRNA nano-
particles, anisamide afforded intracellular uptake of the siRNA cargo
[144]. In a xenograft mouse model, a high extent of tumor localization
was found for both targeted and untargeted nanoparticles, and the
anisamide ligand did not further increase tumor accumulation. Interest-
ingly, these particles showed much higher accumulation in tumor than
in the liver. It is possible that the particle size prevents passage through
liver fenestrations, but this outcome could also be caused by the partic-
ular xenograft model. Although the ligand did not inﬂuence the amount
of nanoparticle delivered to the tumor, only the anisamide-bearing de-
livery system resulted in successful gene silencing.
A trivalent anisamide ligand conjugated to a splice-switching
oligonucleotide showed enhanced cellular uptake in human prostate
carcinoma cells and a four-fold increased biological effect in a reporter
assay cell culture model. Anandamide recognizes the cannabinoid
receptor which is highly expressed on neuronal and immune cells. A
corresponding siRNA conjugate was successfully taken up in these cul-
tured cells and resulted in down regulation of the siRNA-targeted
gene, although high concentrations were required [145].
Similar to small molecule ligands, peptides can be relatively easily
used for attachment to oligonucleotides. Targeting the G-protein
coupled receptor BB2, expressed in many carcinoma cell lines, a
histidine-rich peptide attached to a splice-switching oligonucleotide
was successful in inducing splice correction in a reporter model in a
human prostate cancer cell line [146]. However, only modest pharma-
cological effects were found, and thus the use of this system in a
therapeutic setting is doubtful.
Several antibody-mediated strategies made use of fusion proteins
with basic peptides, such as protamine [126,147–151]. In these cases,
a single chain antibody Fab fragment is fused to a highly cationic peptideto afford siRNA loading through charge complexation. Song et al. were
the ﬁrst to demonstrate antigen-dependent, tissue-speciﬁc gene silenc-
ing by such a system in vivo [147]. Using a Fab fragment with speciﬁcity
to the HIV envelope protein gp160, efﬁcient and speciﬁc siRNA delivery
and effects were found in a xenograft mouse model. Consecutively,
similar approaches used single chain antibody fragments for an integrin
[126], and the hemagluttinin antigen of the avian inﬂuenza virus [149].
Although the fusion proteins are single molecules, they generally form
particle-like structures due to the charge complexation formed between
the cationic peptides and the nucleic acid cargoes. Thus, they show
similar properties as other complexed particles [152], and the fusion
proteins can suffer from poor solubility caused by the high cationic
charge densities. Instead of antibody fragments, alternative protein
binder scaffolds offer easier production, higher stability, andmore facile
derivatization [153]. A Designed Ankyrin Repeat Protein fusion protein
(DARPin) with a protamine fragment was shown to successfully and
speciﬁcally induce gene silencing in an antigen-positive cell line [154].
Recombinant engineering of self-multiplexing proteins yields
well-controlled particles, termed proteinticles, with a uniform size dis-
tribution [155]. A fusion protein with an oligonucleotide complexing
domain, a cell-penetrating peptide, and a targeting peptidewas recently
developed for tumor-speciﬁc delivery of siRNA [156]. Using EGFR- and
vimentin-targeting peptides, successful cellular uptake and gene
silencing was shown in tumor cell lines in vitro. Although the unloaded
proteinticles have a homogenous particle size of around 12 nm, they
aggregate to larger and much more heterogenous particles upon com-
plexation with siRNA. Caused by the surface localization of complexing
peptides, the nucleic acid cargo induces signiﬁcant multiplexing of the
smaller proteinticles. As a consequence, the targeting peptides are
concealed within the aggregates and thus partially unavailable for
receptor-binding. The merit of these proteinticles in an in vivo setting
remains to be elucidated.
Antibody-drug conjugates are attractive molecules for biomedicine
development [157,158]. However, for targeted delivery of siRNA, no
successful use has yet been published. Genentech has recently reported
the generation and development of analytical methodology for an
siRNA–antibody conjugate [159], but to date no pharmacological data
of such compounds have been disseminated. The complex generation
of site-speciﬁc conjugations together with uncertainties about cellular
uptake and intracellular trafﬁcking of the siRNA cargo are possible ex-
planations for the lack of published research in this area. Other protein
scaffolds offer easier derivatization and conjugation possibilities [160].
Oligonucleotides can be site-speciﬁcally attached to protein binders
such as afﬁbodies [161], anticalins [162], or DARPins [154,163]. In the
future, such conjugates could be exploited for the optimal combination
of speciﬁc, highly afﬁne and versatile protein-receptor interaction and
siRNA mediated gene silencing.
2.6. Nanoparticle delivery systems
A wealth of different multi-componential, macromolecular delivery
systems has been developed and evaluated as nucleic acid carriers
(Fig. 1). Many excellent and detailed reviews have been written on
this topic [70,88,164–170]. Themain categories comprise lipid particles,
cationic polymers (PEI, chitosan, polyamines etc.), and cationic pep-
tides. Optimization of these systems by modulation of parameters
such as their component structures, composition, encapsulation or
complexation method and ratio, has increased their efﬁciency and
often reduced their toxicity. In their native form, these delivery systems
all rely on passive targeting in vivo. As described earlier, in correlation to
the particle size and surface composition, this inevitably results in high
accumulation in the kidney, liver and spleen and very limited
concentrations in other organs and tissues. In some cases, the EPR effect
promotes intratumoral accumulation.
In individual cases, speciﬁc untargeted polymers have been reported
to result in signiﬁcant delivery to distinct organs besides the liver. PEI
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livery [171]. The nucleic acid cargo is complexed by electrostatic
interactions resulting in condensed particles. PEI is a heterogeneousFig. 1. Schematic depiction of modalities for targeted siRNA nanoparticles. Oligonucleotides are
somes or polymeric nanoparticles. Complexed cargo can additionally be encapsulated in a lipi
component of the lipid membrane or by post-assembly bioconjugation to reactive surface funcpolymer that is characterized by length, degree of branching, and the
presence of modiﬁcations. Generally, polymerswith increasingmolecu-
lar weight are associated with superior cellular uptake, but suffer fromeither complexed to positively charged polymers or lipids, or encapsulatd in neutral lipo-
d membrane. Ligands for targeted delivery are grafted on the surface by using a modiﬁed
tionalities. Often PEGylation is applied for reduction of unspeciﬁc particle interactions.
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tion of epoxide-modiﬁed pentadecane to the amine of PEI600 in a
molar ratio of 14:1 [174] was evaluated for its pharmacologic effect in
different tissues. Particles generated by condensing siRNA with the
polymer and PEG2000-C14 were shown to be effective for gene silencing
in endothelial cells without affecting hepatocyte gene expression in
mouse models. The endothelial gene silencing was unexpectedly efﬁ-
cient, unlike what has been found for similar, PEI-containing particles.
The molecular reasons for the preference of endothelium are not
known, but it was speculated that it may be caused by a unique proﬁle
of interactions with serum proteins [174].
Despite these individual reports, it seems to be all but essential to
add a ligand for targeted delivery in order to circumvent disposal of
these carrier systems in the liver. This certainly increases the complexity
of the systems, which in themselves are generally consisting of a
delicate mixture of several macromolecules [175]. Ligands can be
attached to an individual component of the delivery system, for
example to one of the lipids making up a liposome, before the ﬁnal
formulation is produced. This approach offers the possibility to purify
the ligand-carrier bioconjugate, and often facilitates reproducibility.
However, the physicochemical parameters during formulation can be
altered by inclusion of a new compound, and it is possible that the
receptor-binding capability is reducedbecause it is not displayed properly
on the particle surface.
The targeting molecule can also be added after constitution of the
ﬁnal oligonucleotide carrier system by chemical ligation to a reactive
group on the carrier surface. A number of attachment chemistries are
at the disposal, including thiol–maleimide attachments, amide-active
ester couplings, and click chemistry alkin–azide cycloadditions [175].
While this strategy provides a straightforward formulation, the ligand
density can often vary according to the available reactive group on the
surface and attachment yields. Usually, it is difﬁcult to assess the actualFig. 2. Overview of bioconjugation techniques and ligand structures. Attachment points at the o
age types are disulﬁde as a labile linker to be cleaved in the endosome, and maleimide or triazligand density afterwards, although it is important for efﬁcient recogni-
tion and internalization [161]. In most cases, multiple ligands will be
displayed at the outer surface of the delivery particle. As a consequence,
the avidity of the particle is high, and the off-rate low, even for low-
afﬁnity receptor ligands. That means that also binding to other targets
(for which the ligand has an inherently low afﬁnity) is a possibility.
The example of the transferrin receptor shows that high afﬁnity can
lead to a higher extent of lysosomal degradation or entrapment in the
microvasculature. Indeed, the amount of transferrin was shown to be
critical for successful transcytosis and detachment on the brain side of
the blood–brain barrier [101].
It is important to acknowledge that the presence of a targeting
ligand can trigger increased retention and cellular uptake through
receptor-mediated endocytosis at the targeted cells, but does not specif-
ically inﬂuence the initial tissue distribution. Blood-half life and extrav-
asation into tissue are nearly exclusively determined by the particle size
and the physicochemical surface properties of the particles. The largest
proportion of nanoparticles is generally found in the liver, kidney and
spleen, and accumulation in tumor tissues is dependent on the proper-
ties (fenestrations) of the adjacent endothelium. Therefore, if targeted
nanoparticles never reach the cell population expressing the respective
antigen, the intended speciﬁc molecular interaction does not happen at
all. On the other hand, surface functionalization alters the physicochemi-
cal parameters, and adding ligands can thus even result in reduced
accumulation in the targeted tissue.
An explanation for the often unexpectedly low performance of
targeted nanoparticlesmay be found in the absorption of serumbiomol-
ecules around the particle surface, referred to as biomolecular corona
[176]. A nearmonolayer forms the initial biocorona, and its composition
is dependent on nanoparticle characteristics and abundances of the dis-
tinct biomolecules in the environment [177]. It consists of proteins, but
also other molecules like lipids. On top of this, a more dynamic secondligonucleotides include primarily the 3′- and 5′-terminal hydroxyl functions. Popular link-
ol linkages derived from click chemistry for stable attachment.
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formed. This biomolecular corona then shifts the nanoparticle proper-
ties from its intrinsic values to those conferred to by the environment.
Absorbed biomolecules such as apolipoproteins can distinctly inﬂuence
the pharmacokinetic properties, and interrupt adequate binding of
grafted targeting ligands. Surface PEGylation generally decreases the
absorption of the biocorona, and thus seems to be crucial to retain the
intended targeting properties [176].
2.7. Bioconjugates for targeted delivery
Being single molecules, siRNA conjugates have very different
properties than those packaged into nanoparticle delivery systems. To
avoid rapid degradation, the siRNA component usually needs to be
chemically modiﬁed, with 2′-O-methylation and 2′-ﬂuoridation being
the most attractive options [54]. Depending on the size of the attached
ligand, renal elimination is a threat. This can be avoided by increasing
the molecular size, for example by PEGylation [178–180]. In contrast
to particle systems, bioconjugates are more readily distributed into
organs, since they are not depending on endothelial fenestrations. Sev-
eral ligands have been used to further increase hepatic accumulation
and uptake, including lipids [181], steroids [182], tocopherol [183],
and carbohydrates [184] (Figure 2). Considering the success of the
GalNAc platform, it is surprising that the concept has not yet been
taken further to achieve accumulation and uptake in other organs.
Smallmolecule ligands can be conjugatedwith relative ease to either
the 3′ or the 5′-end of the sense or antisense strand of the siRNA via
appropriate linkers that are incorporated during automated oligonucle-
otide synthesis [37]. The attachment chemistry can be selected from a
variation of reactions and can be tailored to the distinct ligand. For pep-
tide conjugates, the separately synthesized oligonucleotide and peptide
building blocks can be tethered, or a step-wise solid-phase synthesis of
the two components can be carried out. Because of differing synthesis
procedures and requirements for protecting groups, the latter approach
is more complicated, especially when the peptide exceeds the length of
a few amino acids [185].
It can be assumed that the siRNA needs to be liberated from the
receptor-speciﬁc carrier in order to activate the RNAi machinery. As a
consequence, labile linkages that are designed to be cleaved in the re-
ductive, acidic environment of the endosome, are regarded as beneﬁcial.
But because the exact mechanisms of intracellular processing of such
compounds are not fully understood, the necessity for detachment
from the targeting ligand is not conﬁrmed and may be dependent on
the speciﬁc carrier molecule. The example of the trivalent GalNAc
conjugates shows that stable linkages do not prevent efﬁcient gene
silencing in all cases.
Often, multivalent linkages show superior cell binding and uptake
characteristics, caused by an increase of avidity by the ability for simul-
taneous binding to several surface receptors. To achieve this, the spatial
arrangement and distance between the ligands is of importance.
3. Conclusion
The decade-long research and development of siRNA delivery
systems has taught us important lessons and identiﬁed some key
parameters. The efﬁcacy of nanoparticle structures relies heavily on
size, material characteristics and surface properties. Optimal size is
important to prevent rapid elimination (for small particles) and clear-
ance by the reticuloendothelial system (for large particles). Depending
on the particular material, an optimal size range of about 50–200 nm
has been established. Porosity is a key issue for water penetration,
payload release and degradation characteristics. Surface PEGylation
helps avoiding immune system activation and capture by immune
cells, but generally reduces uptake and cargo release. Cationic charges
on the other hand are thought to increase intracellular delivery by
enhancing cellular association and by disrupting the endosomal systemthrough their pH buffering capacity, but they also increase non-speciﬁc
interaction with cells, including those of the immune system, and can
cause toxicity.
These rules help in the design of nanocarriers, but do not encompass
all aspects. The immunogenicity and toxicity effects are largely unpre-
dictable, and the extent of successful functional delivery is often
surprisingly low. More detailed knowledge of exact cellular uptake
events and intracellular trafﬁcking and endosomal sorting is required
for improving the rational carrier design [186]. When using receptor-
mediated uptake, bioconjugates with high-afﬁnity ligands increase
speciﬁc cell association and accumulation in the targeted organ or
tissue. Similar to particle systems, the extent of cytosolic delivery
seems to be heavily dependent on endosomal escape and the cellular
sorting machinery. Closer insight is essential for optimal selection of a
receptor for targeting and its corresponding ligand as well as ﬁnding
viable strategies for increasing functional uptake at the extent of
lysosomal degradation.
There is also an increasing translational gap. Academic nanotechnology
research often develops increasing complex cutting-edge systems in order
to factor in the latest insights of uptake mechanism. Hindered by issues of
characterization, manufacturing, and toxicity, many of these sophisticated
approacheshaveultimately little chanceof a translation to a clinical setting.
On the other hand, simple reduced solutions have won market approval
and have shown improved pharmacotherapy with doxorubicine or pacli-
taxel, but show little promise for smooth adaptation to biomacromolecule
delivery.
For siRNA delivery, two modalities have been successful in preclini-
cal and early clinical testing, both for liver targeting: Encapsulation in
engineered lipid particles designed for nucleic acids (SNALPs), and con-
jugates of the cargo with N-acetyl galactosamine, an asialoglycoprotein
receptor ligand. Starting from these, an evolution to expand siRNA
therapy to other sites seems to be more easily achievable for bioconju-
gates, for which the receptor ligand can be switched with ease. The
progression of lipid particles is ostensibly much more complicated,
because the liver accumulation is triggered by both lipophilicity and
particle size. While the surface characteristics can be modulated by
structural engineering (PEGylation, attachment of targeting moieties),
their particle size will still direct them to the liver, and tissues with
tight endothelial junctions are all but excluded. Signiﬁcant progress
can possibly be achieved by the development of efﬁcient nanoparticle
targeting strategies.
The increasing understanding of both basic mechanisms of
cellular uptake and trafﬁcking and the structural and biophysical
requirements for successful siRNA delivery systems gives reasons
to anticipate signiﬁcant progress in this ﬁeld in the near future.
Ultimately, successful therapeutic translation and subsequent
clinical outcomes within the next decade will decide the impact of
siRNA therapies in medicine.
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